PLx Pharma Inc. to Discuss 2021 Second Quarter Financial Results on August 6, 2021 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) announced it will release its 2021 second quarter financial results on August 6, 2021, before U.S. markets open. A conference call hosted by CEO Natasha Giordano and CFO Rita O’Connor will provide insights into the results and business updates, starting at 8:30 a.m. ET. VAZALORE™, the company’s FDA-approved liquid-filled aspirin capsule, offers improved platelet inhibition and reduced risk of stomach issues compared to traditional aspirin, targeting patients with vascular disease and diabetes.
- Launch of VAZALORE, providing effective aspirin therapy with reduced side effects.
- FDA approval of VAZALORE, enhancing credibility and market potential.
- None.
SPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), announced today that the Company will release its 2021 second quarter financial results on Friday, August 6, 2021, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
| Date | Friday, August 6, 2021 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | (866) 394-2901 |
| International Conference ID | (616) 548-5567 8277376 |
| Webcast (live and replay) | www.plxpharma.com under the ‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8277376. The archived webcast will be available for 30 days via the aforementioned URL.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will PLx Pharma release its second quarter financial results for 2021?
What is VAZALORE and its benefits?
Who will host the conference call for PLx Pharma's financial results?
What time is the PLx Pharma conference call on August 6, 2021?
How can I access the replay of PLx Pharma's conference call?
